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159 Fundoplication for reﬂux induced cough in cystic ﬁbrosis
N.M. Haley, T.M. Moon, A.H. Morice. Respiratory Medicine, University of Hull,
Hull, United Kingdom
Reﬂux induced cough in patients with cystic ﬁbrosis (CF) is a common but poorly
recognised problem. Laparoscopic fundoplication may be a treatment for patients
not responding to maximal medical therapy. Operative treatment may have the
additional beneﬁt of preventing non acid as well as acid reﬂux.
Patients with reﬂux cough were identiﬁed by the characteristic clinical history of
extra-oesophageal reﬂux. Patients were offered fundoplication following failure of
maximal medical therapy. All underwent oesophageal pH and manometry studies
prior to surgery. Symptoms were assessed by the Leicester Cough Questionnaire
(LCQ). Spirometry was performed pre- and postoperatively.
Four patients underwent fundoplication. The mean DeMeester score preoperatively
was 45.5 (normal 14.8). Mean number of reﬂux episodes of 156 (normal 50).
Longest episode lasted 54 minutes (mean 22.5 mins, normal 10 mins). Reported
cough was highly associated with reﬂux episodes. Following surgery LCQ scores
improved from a mean (range) of 68 (52−82) preop to 110 (100–124) afterwards.
Spirometry increased from a mean of 0.86 to 0.93 (FEV1) and 2.17 to 2.36 (FVC).
Reﬂux symptoms and quality of life were improved after fundoplication in this
group of patients with proven acid reﬂux disease. Early spirometry improved a
little but there was a trend to reduced exacerbation rate. Fundoplication appears
safe even in this group of patients with marked spirometric impairment.
Recent studies indicate that surgery has an increasingly important role in treating
reﬂux in patients requiring lung transplantation. Early fundoplication has been
shown to reduce rates of bronchiolitis obliterans syndrome (BOS) and survival
post transplant. We suggest agressive investigation and treatment for CF patients
with the persistent dry cough characteristic of reﬂux.
160 Determinants of delivered dose from the I-neb® AAD® System
R.W. Potter, R.H. Hatley. Respironics Respiratory Drug Delivery (UK) Ltd,
Chichester, West Sussex, United Kingdom
The I-neb® AAD® System has been designed to deliver precise doses of drug to
the patient. It is approved as a general purpose nebulizer in the EU and cleared for
use with Ventavis® in the USA. The delivered volume is determined either by the
volume of the metering chamber, or by the volume metered into the medication
chamber. The metered volume (MV) and the drug concentration should therefore be
important determinants of the delivered dose (DD). In order to test the hypothesis,
we have analyzed the MVs and DDs of four drugs used in the treatment of patients
with cystic ﬁbrosis.
Three I-nebs for each drug tested were connected via a ﬁlter to a Harvard pump
set to generate the CEN simulated breathing pattern. For tobramycin 1.5mL was
metered into the medication chamber, a metering chamber of delivery volume
0.3mL was used for the three other drugs. The MV was assessed using a gravimetric
method and was used to calculate the expected DD (the product of the MV
and the drug concentration). The actual DD was assessed using a bioassay for
colistimethate sodium, HPLC for tobramycin, and spectrophotometry for dornase
alfa and salbutamol. Tests were performed in triplicate for each device/drug
combination.
The calculated DD approximated the measured DD for each of the drugs, which
proves the hypothesis that the MV and drug concentration are important determi-
nants of the DD.
Precise doses of tobramycin, colistimethate sodium, dornase alfa and salbutamol
sulphate can be delivered into simulated breathing by the I-neb AAD System.
Drug MV* (SD) Drug concentration Calculated DD Measured DD (SD)
Tobramycin 1456mL (49mL) 60mg/1mL 87.36mg 75.9mg (6.6mg)
Colistimethate sodium 311.2mL (18.0mL) 1MIU/1mL 311.2 kIU 324.9 kIU (15.8 kIU)
Dornase alfa 318.3mL (5.3mL) 1,000U/1mL 318.3U 296.7U (13.9U)
Salbutamol sulphate 317.2mL (6.0mL) 2.0mg/1mL 634.4mg 605.1mg (10.1mg)
* minus 0.1 mL residual volume in the medication chamber for tobramycin.
161 PortaNeb® or CR60®? Inhalation of tobramycin (TOBI®) with the
Pari LC Plus® nebuliser: an in vivo pilot study
E.M. Westerman1,3, D.J. Touw1,3, H.G. Heijerman2. 1Apotheek Haagse
Ziekenhuizen, The Hague, Netherlands; 2Adult CF Center, Haga Teaching
Hospital, The Hague, Netherlands; 3Haga Teaching Hospital, The Hague,
Netherlands
Aim: The CR60® compressor produces small particles and is said to shorten
nebulisation time. Two compressors (CR60® and PortaNeb® (PN)) for inhalation
of tobramycin (Tobi®) were compared, using the Pari LC Plus® (PLP) nebuliser,
in a pilot study. The pharmacokinetics (PK; safety (Cmax)), pulmonary deposition
(AUC0−6), nebulisation time, bronchoconstriction and patient’s experience were
compared.
Methods: Ten CF patients participated in an open, randomised cross-over study
with 300mg tobramycin using both compressors. FEV1 and FVC were registered
before and after inhalation. Tobramycin lung deposition was indirectly determined
by measuring tobramycin serum concentrations and PK analysis. The patient’s
experience was documented using a questionnaire. The Wilcoxon signed ranks test
was used for statistical analysis. Results are presented as median and range.
Results: PK: Cmax: CR60 0.70 (0.53−2.49) vs PN 0.54 (0.41−1.95) mg/L,
p = 0.005) and AUC0−6: (CR60 2.54 (1.98−6.65) vs PN 2.01 (1.55−6.18)
h.mg/L, p = 0.017) were different. Tmax CR60 was earlier (0.64 (0.59−0.72) vs
0.85 (0.78−1.13) h, p = 0.005). Lung function tests indicated bronchoconstriction
in 3 patients (2xPN;1xCR60) versus subjective experienced chest tightness in
7 patients (CR60® >PN).
No differences were observed regarding ease of administration and noise. A shorter
nebulisation time of 13.2 (11.1−15.8) min was observed (CR60®), compared to PN
16.1 (11.8−19.4) min (p = 0.022), which was the main reason why patients preferred
the CR60® (n = 7).
Conclusion: Inhalation of tobramycin (TOBI®) is safe using the PLP nebuliser
and PN or CR60® compressor. The latter may be advantageous due to a shorter
nebulisation time and larger pulmonary deposition. The patient’s preference is of
critical importance.
162 Characteristics of the patients with cystic ﬁbrosis
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Objective: To demonstrate the clinical and laboratory characteristics of the patients
with cystic ﬁbrosis.
Material and Methods: The data ﬁles of 49 patients with cystic ﬁbrosis followed by
Department of Pediatrics in Dokuz Eylul University were evaluated retrospectively.
Results: Sixteen (32.7%) of 49 patients were girls, 33 (67.3%) were boys. The
ages of patients varied between 8–239 months (85.9±53.3) and the ages at the
diagnosis varied between 1.5 and 168 months (31.2±41.4). Consanguity was found
in 13 (26.6%) of the patients’ parents. Two of the patients had siblings with cystic
ﬁbrosis. All of them except one had ﬁndings of pulmonary involvement, 29 (59.2%)
exocrine pancreas insufﬁciency, 22 (44.9%) malnutrition, 21 (42.9%) recurrent
diarrhea, nine (18.4%) pseudobartter syndrome and one (2%) meconium ileus in
the newborn period. Three (6.1%) patients died because of respiratory failure. The
sweat tests varied between 68–172mEq/L (101.7±22.6). The mutation rate that
was detected in our patients is 35.2%. Pseudomonas aeruginosa colonisation was
found in six (12.2%) patients and multiresistant Pseudomonas aeruginosa in two
(4.1%) of them. Fifteen (30.6%) patients recieved inhaled steroid, 21 (42.9%)
bronchodilatator, ﬁve (10.2%) aerosolized antibiotic therapy and ﬁve (10.2%)
recombinant human deoxyribonuclease therapy.
